Pembrolizumab and radiation therapy for multifocal myxofibrosarcoma of the scalp: a case report

被引：0

作者：

Grant, Christopher Ryan ^{[1
]}

Arter, Zhaohui ^{[2
]}

Smith, Janellen ^{[3
]}

Seyedin, Steven N. ^{[4
]}

Nourbakhsh, Mahra ^{[5
]}

Lee, Bonnie ^{[3
,5
]}

Creadore, Andrew ^{[3
]}

Mar, Nataliya ^{[2
]}

机构：

[1] Univ Calif Irvine, Med Ctr, Dept Med, 101 City Dr South, Orange, CA 92868 USA

[2] Univ Calif Irvine, Med Ctr, Div Hematol Oncol, Orange, CA USA

[3] Univ Calif Irvine, Med Ctr, Dept Dermatol, Orange, CA USA

[4] Univ Calif Irvine, Med Ctr, Dept Radiat Oncol, Orange, CA USA

[5] Univ Calif Irvine, Med Ctr, Dept Pathol, Orange, CA USA

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2024年 / 16卷

关键词：

immune checkpoint inhibitor; myxofibrosarcoma; pembrolizumab; soft tissue sarcoma; SOFT-TISSUE SARCOMA; OPEN-LABEL; MULTICENTER; IMMUNOTHERAPY; CHEMOTHERAPY; PAZOPANIB; CANCER; GRADE;

D O I：

10.1177/17588359241259451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myxofibrosarcoma is one of the most common types of soft tissue sarcomas occurring in the lower limbs of male older adults. Mainstay treatment is surgical intervention with chemoradiotherapy with a combination of doxorubicin and ifosfamide with brachytherapy if advanced or metastatic. There are no guidelines on the combination of immunotherapy with radiation therapy for myxofibrosarcoma. We report the first documented case of unresectable multifocal myxofibrosarcoma that was treated with pembrolizumab and radiation therapy for first-line therapy with a significant response. We also highlight genomic markers and immune radiation priming therapy, forecasting favorable response in treatment with pembrolizumab.

引用

页数：9

共 42 条

[41] Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial
Weiss, Aaron R.
Chen, Yen-Lin
Scharschmidt, Thomas J.
Chi, Yueh-Yun
Tian, Jing
Black, Jennifer O.
Davis, Jessica L.
Fanburg-Smith, Julie C.
Zambrano, Eduardo
Anderson, James
Arens, Robin
Binitie, Odion
Choy, Edwin
Davis, Justin W.
Hayes-Jordan, Andrea
Kao, Simon C.
Kayton, Mark L.
Kessel, Sandy
Lim, Ruth
Meyer, William H.
Million, Lynn
Okuno, Scott H.
Ostrenga, Andrew
Parisi, Marguerite T.
Pryma, Daniel A.
Randall, R. Lor
Rosen, Mark A.
Schlapkohl, Mary
Shulkin, Barry L.
Smith, Ethan A.
Sorger, Joel, I
Terezakis, Stephanie
Hawkins, Douglas S.
Spunt, Sheri L.
Wang, Dian
[J]. LANCET ONCOLOGY, 2020, 21 (08) : 1110 - 1122
[42] Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
Zhou, Maggie
Bui, Nam
Lohman, Marta
van de Rjin, Matt
Hwang, Gloria
Ganjoo, Kristen
[J]. CASE REPORTS IN ONCOLOGY, 2021, 14 (01): : 459 - 465

← 1 2 3 4 5 →